Leucine supplementation modulates lipid metabolism and metabolic pathways in mice with type 1 diabetes: A metabolomics study

Type 1 diabetes mellitus (T1DM) is an autoimmune destruction of pancreatic β-cells that causes absolute insulin deficiency and lifelong insulin use. It leads to ketoacidosis and long-term micro-/macro-vascular complications. Globally, ~9 million individuals live with T1DM and ~0.5 million are newly diagnosed each year. Leucine (Leu), a branched-chain amino acid, improves blood-glucose control and increases the insulin sensitivity of peripheral tissues. However, its role in modulating lipid metabolism and metabolic pathways in T1DM is yet to be elucidated. In the present study, male C57BL/6J mice were randomly divided into four groups, namely Normal, Normal-Leu, T1DM and T1DM-Leu. T1DM was induced by five daily intraperitoneal injections of streptozotocin (50 mg/kg per day), and leucine was provided in the drinking water at 1.5% (w/v) for 6 weeks. After 6 weeks, plasma samples were collected for metabolomics and biochemical analysis. Untargeted LC-MS/MS profiling showed elevated metabolites mapping to steroid-hormone biosynthesis, arachidonic/linoleic-acid and retinol pathways in T1DM vs. Normal; Leu partly lowered these signals and shifted galactose and primary bile-acid metabolism toward control patterns. Leu supplementation downregulated galactose-pathway intermediates and reduced signals consistent with primary bile-acid biosynthesis, shifting both pathways toward control levels in T1DM-Leu vs. T1DM. Biochemically, T1DM lowered high-density lipoprotein (HDL) and raised low-density lipoprotein (LDL) vs. Normal (HDL, 0.597±0.292 mmol/l; LDL, 1.154±0.501 mmol/l); with Leu, these lipids approached control levels: T1DM-Leu (HDL, 0.958±0.224 mmol/l; LDL, 0.548±0.267 mmol/l) vs. Normal-Leu (HDL, 0.912±0.121 mmol/l; LDL, 0.392±0.175 mmol/l). In summary, the findings of the present study indicated that dietary Leu may be a useful adjuvant for T1DM due to potentially easing dyslipidemia and reversing key metabolic disturbances.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2025-11-06
DOI
https://doi.org/10.3892/etm.2025.13012
Primary Topic
Muscle metabolism and nutrition
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Leucine supplementation modulates lipid metabolism and metabolic pathways in mice with type 1 diabetes: A metabolomics study

Jeng-Yuan Yao, Cai-Hong Feng, Tongjian You, G Xiao et al.
Experimental and Therapeutic Medicine
Muscle metabolism and nutrition
article

Leucine supplementation modulates lipid metabolism and metabolic pathways in mice with type 1 diabetes: A metabolomics study

Jeng-Yuan Yao, Cai-Hong Feng, Tongjian You, G Xiao, Diana Y. Tzeng, Ru-Yu Zheng
article en

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune destruction of pancreatic β-cells that causes absolute insulin deficiency and lifelong insulin use. It leads to ketoacidosis and long-term micro-/macro-vascular complications. Globally, ~9 million individuals live with T1DM and ~0.5 million are newly diagnosed each year. Leucine (Leu), a branched-chain amino acid, improves blood-glucose control and increases the insulin sensitivity of peripheral tissues. However, its role in modulating lipid metabolism and metabolic pathways in T1DM is yet to be elucidated. In the present study, male C57BL/6J mice were randomly divided into four groups, namely Normal, Normal-Leu, T1DM and T1DM-Leu. T1DM was induced by five daily intraperitoneal injections of streptozotocin (50 mg/kg per day), and leucine was provided in the drinking water at 1.5% (w/v) for 6 weeks. After 6 weeks, plasma samples were collected for metabolomics and biochemical analysis. Untargeted LC-MS/MS profiling showed elevated metabolites mapping to steroid-hormone biosynthesis, arachidonic/linoleic-acid and retinol pathways in T1DM vs. Normal; Leu partly lowered these signals and shifted galactose and primary bile-acid metabolism toward control patterns. Leu supplementation downregulated galactose-pathway intermediates and reduced signals consistent with primary bile-acid biosynthesis, shifting both pathways toward control levels in T1DM-Leu vs. T1DM. Biochemically, T1DM lowered high-density lipoprotein (HDL) and raised low-density lipoprotein (LDL) vs. Normal (HDL, 0.597±0.292 mmol/l; LDL, 1.154±0.501 mmol/l); with Leu, these lipids approached control levels: T1DM-Leu (HDL, 0.958±0.224 mmol/l; LDL, 0.548±0.267 mmol/l) vs. Normal-Leu (HDL, 0.912±0.121 mmol/l; LDL, 0.392±0.175 mmol/l). In summary, the findings of the present study indicated that dietary Leu may be a useful adjuvant for T1DM due to potentially easing dyslipidemia and reversing key metabolic disturbances.

Experimental and Therapeutic MedicineVol. 31(1)
Fujian Medical University (CN), Xiamen University (CN), Xiamen Medical College
Natural Science Foundation of Fujian Province
Openalex Percentile: Top 66%
Muscle metabolism and nutrition
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.